Early Complete Molecular Response to First-Line Nilotinib in Two Patients with Chronic Myeloid Leukemia Carrying the p230 Transcript-Reference-Cited by-同舟云学术

Early Complete Molecular Response to First-Line Nilotinib in Two Patients with Chronic Myeloid Leukemia Carrying the p230 Transcript

Published:2013 Issue: Volume:2013 Page:1-2
ISSN:2090-6560
Container-title:Case Reports in Hematology
language:en
Short-container-title:Case Reports in Hematology

Author:

Greco Marianna¹^ORCID,Caocci Giovanni¹²^ORCID,La Nasa Giorgio¹²

Affiliation:

1. Hematology Unit and Bone Marrow Transplantation Center, “R. Binaghi” Hospital, Via Is Guadazzonis 3, 09126 Cagliari, Italy

2. Hematology, Department of Medical Sciences, University of Cagliari, 09100 Cagliari, Italy

Abstract

Chronic myeloid leukemia (CML) with the rare fusion gene e19a2, encoding a p230 protein, has been described in patients with typical or rather aggressive clinical course. Although tyrosine kinase inhibitors (TKIs) induce a substantial cytogenetic and molecular response in all phases of CML, a minority of p230 positive patients have been treated with TKIs. We report two cases of CML patients carrying the p230 transcript, who achieved fast and deep complete molecular response (CMR) after frontline treatment with nilotinib. Our results suggest the use of nilotinib as frontline agent for the treatment of this CML variant.

Publisher

Hindawi Limited

Subject

Cell Biology,Developmental Biology,Embryology,Anatomy

Link

http://downloads.hindawi.com/journals/crihem/2013/871476.pdf

Reference10 articles.

1. New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia

2. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction) [see comments]

3. Blast crisis of Philadelphia chromosome-positive chronic myeloid leukaemia carrying micro-bcr breakpoint (e19a2 and e191a)

4. Cloning and molecular characterization of a novel gene strongly induced by the adenovirus E1A gene in rat thyroid cells

5. e19a2 BCR-ABL fusion transcript in typical chronic myeloid leukaemia: a report of two cases

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic myeloid leukemia with variant e19a2 BCR-ABL1 fusion transcript: interest of the molecular identification at diagnosis for minimal residual disease follow-up;Annales de biologie clinique;2014-05

2. Molecular Response to Nilotinib in a Patient with Imatinib-intolerant e19a2-positive Chronic Myeloid Leukemia;Internal Medicine;2014

3. Nilotinib for the Frontline Treatment of Chronic Myeloid Leukemia Carrying the p230 Transcript: Dream or Reality?;Frontiers in Oncology;2014

4. Chronic myeloid leukemia carrying “micro”-bcr breakpoint;Tenri Medical Bulletin;2014